Cancer of Prostate, Cancer of the Prostate, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Prostate Cancer, Prostate Neoplasm, Prostatic Cancer
Conditions
Keywords
Phase 1, Phase 2, metastatic castration-resistant prostate cancer, NUV-422, enzalutamide, Xtandi, CDK, CDK inhibition, CDK2/4/6
Brief summary
NUV-422-04 is an open-label Phase 1b/2 dose escalation and expansion study designed to evaluate the safety and efficacy of NUV-422 in combination with enzalutamide. The study population is comprised of adults with mCRPC. Patients will self-administer NUV-422 and 160 mg enzalutamide orally in 28-day cycles. Patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.
Interventions
DRUGNUV-422
NUV-422 is an investigational drug for oral dosing.
DRUGEnzalutamide
Enzalutamide
Sponsors
Nuvation Bio Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Diagnosis of metastatic castration-resistant prostate cancer with disease progression despite castrate levels of testosterone 2. Have radiographic or biochemical evidence of progression as determined by Investigator per standard criteria 3. Have no known active or symptomatic central nervous system (CNS) disease 4. Prior therapy with abiraterone required and: * For Phase 1b only: up to 2 prior taxane-based chemotherapy regimens allowed for castration-resistant disease * For Phase 2 only: Patients must not have received prior taxane-based chemotherapy for castrate-resistant disease or prior treatment with CDK inhibitors 5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2 6. Adequate bone marrow and organ function 7. Eligible to receive enzalutamide 8. Life expectancy of \> 6 months
Exclusion criteria
1. History of seizure or any condition that may predispose to seizure (prior cortical stroke or significant brain trauma) 2. Have received chemotherapy, hormonal therapy (with the exception of ongoing LHRH analogs) radiation, or biological anti-cancer therapy within 14 days prior to first dose of NUV-422 and enzalutamide 3. Received treatment with an investigational agent for any indication within 14 days for non-myelosuppressive agent or 21 days (or \< 5 half-lives) for myelosuppressive agent prior to the first dose of NUV-422 and enzalutamide 4. Requires medications that are known to be strong inducers and /or inhibitors of CYP3A4/5 enzymes, except enzalutamide * For Phase 1b only: Requires medications that are known to be moderate inducers and /or inhibitors of CYP3A4/5 enzymes, except enzalutamide 5. Prior therapy with enzalutamide, apalutamide, darolutamide, or investigational androgen receptor inhibitors 6. Known allergy or hypersensitivity to enzalutamide
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b Dose Escalation: Safety and tolerability of NUV-422 in combination with enzalutamide to determine the recommended Phase 2 combination dose (RP2cD) | During the DLT period (28 days) | Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and laboratory abnormalities |
| Phase 2 Dose Expansion: Prostate-specific antigen (PSA)-response rate (PSA-RR) | Every 4 weeks throughout study treatment, an average of 6 months | PSA per standard criteria |
| Phase 2 Dose Expansion: Objective response rate (ORR) | Every 8 weeks throughout study treatment, an average of 6 months | ORR per standard criteria |
Countries
United States
Outcome results
None listed